{
    "clinical_study": {
        "@rank": "131075", 
        "arm_group": [
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin, fed", 
                "arm_group_type": "Active Comparator", 
                "description": "3 single tablets under fed conditions"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1500 mg Metformin FDC", 
                "arm_group_type": "Experimental", 
                "description": "2 FDC tablets under fasted conditions"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1500 mg Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "4 single tablets under fasted conditions"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin FDC", 
                "arm_group_type": "Experimental", 
                "description": "1 fixed dose combination(FDC) tablet under fasted conditions"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin", 
                "arm_group_type": "Active Comparator", 
                "description": "3 single tablets under fasted conditions"
            }, 
            {
                "arm_group_label": "5mg Linagliptin/1000mg Metformin, FDCfed", 
                "arm_group_type": "Experimental", 
                "description": "1 FDC tablet under fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed\n      fixed dose combination (FDC) tablets containing linagliptin & metformin and the single\n      tablets of linagliptin and metformin when administered singularly."
        }, 
        "brief_title": "Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Healthy males or females\n\n          2. Age 18 -50 years (incl)\n\n          3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)\n\n          4. Subjects must be able to understand and comply with study requirements\n\n        Exclusion criteria:\n\n        Any deviation from healthy condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845077", 
            "org_study_id": "1288.8"
        }, 
        "intervention": [
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin, fed", 
                "description": "2 tablets", 
                "intervention_name": "2x500 mg Metformin (Glumetza)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5mg Linagliptin/1000mg Metformin, FDCfed", 
                "description": "FDC tablet", 
                "intervention_name": "5 mg Linagliptin/1000 mg Metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin, fed", 
                "description": "1 tablet", 
                "intervention_name": "5 mg Linagliptin (Tradjenta)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin", 
                "description": "1 tablet", 
                "intervention_name": "5 mg Linagliptin (Tradjenta)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1500 mg Metformin", 
                "description": "3 tablets", 
                "intervention_name": "3x500 mg Metformin (Glumetza)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1500 mg Metformin", 
                "description": "1 tablet", 
                "intervention_name": "5 mg Linagliptin (Tradjenta)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin", 
                "description": "2 tablets", 
                "intervention_name": "2 x 500 mg Metformin (Glumetza)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1000 mg Metformin FDC", 
                "description": "FDC Tablet", 
                "intervention_name": "5 mg Linagliptin/1000mg Metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg Linagliptin/1500 mg Metformin FDC", 
                "description": "2 FDC tablets", 
                "intervention_name": "2 x 2.5 mg Linagliptin/750 mg Metformin FDC", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "BI 1356", 
                "Metformin"
            ]
        }, 
        "lastchanged_date": "August 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "1288.8.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Relative Bioavailability of Two Newly Developed Extended Release FDC Tablet Strengths (5mg/1000mg and 2.5 mg/750 mg) of Linagliptin/Metformin Extended Release Compared With the Free Combination of Linagliptin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC 0-72 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 72 hours); Linagliptin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma); Linagliptin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }, 
            {
                "measure": "AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point); Metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }, 
            {
                "measure": "Cmax; Metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Linagliptin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }, 
            {
                "measure": "AUC 0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity); Metformin", 
                "safety_issue": "No", 
                "time_frame": "up to 72 h post dose"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}